Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO
A week after updating their S-1 in search of at least $115 million on the hot biotech IPO market, Poseida Therapeutics says it’s also raised a fresh venture round — a little more than a year after its last.
The first time around, after Poseida delayed its IPO during a government shutdown, the biotech reported a $150 million C round. This time around, it’s adding $110 million more from Fidelity Management Research Company and others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.